|
 The National Pharmaceutical Pricing Authority (NPPA) has notified the retail prices of 11 new drugs, fixed in its recent meeting, under the provisions of the Drugs Prices Control Order (DPCO), 2013, including several anti-hypertensive and antibiotic medicines.
The pricing authority fixed prices of two strengths of combination drug bisoprolol fumarate and telmisartan tablets marketed by Intas Pharmaceuticals, two strengths of combination of antibiotic ceftriaxone and sulbactam for injection from Dr Reddy's Laboratories, and two strengths of combination of ceftriaxone, disodium edetate and sulbactam powder for solution for infusion marketed by Criticare Division LLP.
Retail price of an antiallergic drug combination of levocetirizine dihydrochloride and montelukast sodium syrup and anti hypertensive drug telmisartan and hydrochlorothiazide tablets marketed by SRK Puremed LLP, telmisartan and amlodipine tablet combination from Unison Pharmaceuticals, and cefixime and ofloxacin oral suspension from Cachet Pharmaceuticals.
The list of medicines for which prices were fixed and notified now include a particular strength of anti-diabetic combination of teneligliptin, dapagliflozin, and metformin sustained release tablet from Glenmark Pharmaceuticals.
Earlier, on October 30, 2025, the Authority has fixed the retail price of 28 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including several anti-diabetic, anti-hypertensive, and respiratory medicines.
These are new drugs, under paragraph 2(1)(u) of the Drugs Prices Control Order (DPCO), 2013.
Under the Paragraph 2(1)(u) of the DPCO, 2013, a new drug is defined as a formulation launched by an existing manufacturer of a drug of specified dosages and strengths as listed in the National List of Essential Medicines (NLEM) by combining the drug with another drug either listed or not listed in the NLEM or a formulation launched by changing the strength or dosages or both of the same drug of specified dosages and strengths as listed in the NLEM.
The methodology of calculating and fixing the retail price of new drugs for existing manufacturers of scheduled formulations are specified in the Para 5 and 15 of the DPCO, 2013, which is followed by the NPPA to arrive at the price against the applications submitted by the companies.
In case the retail price of any of these formulations are not complied with, as per the price notifications and notes released by the authority, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955, added the price regulator.
|